SCHEMBL6077308

SCHEMBL6077308

CN(Cc1ccc(Cl)c(Cl)c1)C(=O)/C=C1/OC(C)(C)OC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.47
TRPV1 Q8NER1 1/20 0.39
PDPK1 O15530 1/20 0.37
PYCR1 P32322 1/20 0.36
CXCR3 P49682 1/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
ROCK2 O75116 1/20 0.35
APAF1 O14727 1/20 0.35
UBE2N P61088 1/20 0.35
CENPE Q02224 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
ALDH1A1 P00352 1/20 0.34
TACR3 P29371 1/20 0.34
TSHR P16473 1/20 0.34
TBXA2R P21731 1/20 0.34
PTGER1 P34995 1/20 0.34
PTGER4 P35408 1/20 0.34
PTGFR P43088 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077313 1.00 USP30 (0.47) USP30TRPV1PDPK1PYCR1CXCR3
SCHEMBL6416220 0.90 USP30 (0.39) USP30CXCR3CENPEALDH1A1TACR3
SCHEMBL6416216 0.90 USP30 (0.39) USP30CXCR3CENPEALDH1A1TACR3
SCHEMBL6420127 0.90 USP30 (0.39) USP30ALDH1A1
SCHEMBL6420129 0.90 USP30 (0.39) USP30ALDH1A1
SCHEMBL6417430 0.87 POLB (0.38) USP30PDPK1ALDH1A1
SCHEMBL6417431 0.87 POLB (0.38) USP30PDPK1ALDH1A1
SCHEMBL6077341 0.87 ALDH1A1 (0.46) ALDH1A1
SCHEMBL6076726 0.87 CDK8 (0.38) USP30PDPK1SIGMAR1ALDH1A1TSHR
SCHEMBL6414063 0.86 RIPK1 (0.47) PYCR1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF USP30 4172/4885TRPV1 4770/4885PDPK1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.